Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Arcutis Biotherapeutics (Nasdaq: ARQT) granted an aggregate of 143,500 restricted stock units and options to purchase 37,000 shares of common stock to 24 newly hired employees under its 2022 Inducement Plan, effective August 3, 2026, in accordance with Nasdaq Listing Rule 5635(c)(4).
The RSUs vest in four equal annual installments over four years, subject to continued employment. The stock options have a ten-year term, vest over four years with a one-year cliff then monthly vesting, and carry an exercise price of $25.94 per share, equal to the August 3, 2026 Nasdaq closing price.
Positive
- None.
Negative
- None.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Aug 05 | Q2 earnings report | Positive | -2.5% | Q2 product revenue rose 59%; guidance increased to $525–$540 million. |
| Jul 16 | Board appointment | Positive | -0.1% | Board appointment added a director with stated growth and ZORYVE experience. |
| Jul 15 | Earnings scheduling | Neutral | -0.1% | Scheduled Q2 results release and conference call for August 5, 2026. |
| Jul 08 | FDA application acceptance | Positive | +3.0% | FDA accepted infant atopic dermatitis sNDA; PDUFA date set for February 23, 2027. |
| Jul 02 | Inducement grants | Neutral | +1.0% | Granted 61,000 RSUs to nine newly hired employees under inducement plan. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent positive company updates produced mixed reactions: the Q2 earnings release diverged, while FDA acceptance aligned with a positive reaction.
Key Terms
restricted stock units financial
stock options financial
inducement plan financial
nasdaq listing rule 5635(c)(4) regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
WESTLAKE VILLAGE, Calif., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the grant of an aggregate of 143,500 restricted stock units (RSUs) of Arcutis’ common stock as well as options to purchase an aggregate of 37,000 shares of Arcutis’ common stock to 24 newly hired employees. These awards were approved by the Compensation Committee of Arcutis’ Board of Directors and granted under the Arcutis Biotherapeutics, Inc. 2022 Inducement Plan, with a grant date of August 3, 2026, as a material inducement to the new employees in connection with their commencement of employment with Arcutis, in accordance with Nasdaq Listing Rule 5635(c)(4).
The RSUs will vest over four years, with 25 percent vesting on each annual anniversary of the vesting commencement date, subject to each employee’s continued employment with Arcutis through the applicable vesting date. The stock options vest over four years, with 25 percent vesting on the one-year anniversary of the vesting commencement date for such employee and the remainder vesting in 36 equal monthly installments over the following three years, subject to the employee being continuously employed by Arcutis as of such vesting dates. The stock options have a ten-year term and an exercise price of
Arcutis is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4).
About Arcutis
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a commercial-stage medical dermatology company delivering meaningful innovation to address the needs of individuals living with chronic inflammatory skin diseases. Over the past decade, Arcutis has successfully developed a robust portfolio of advanced targeted topicals approved to treat three major inflammatory skin diseases, driven by a commitment to solving the most persistent patient challenges in dermatology. Arcutis’ unique dermatology development platform, built on established scientific pathways and coupled with deep clinical dermatology and commercial expertise, enables us to efficiently develop, scale, and deliver our differentiated therapies while advancing a growing pipeline across a range of inflammatory dermatological conditions. For more information, visit www.arcutis.com or follow Arcutis on LinkedIn, Facebook, Instagram, and X.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. For example, statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on the Company’s current beliefs and expectations and are subject to substantial known and unknown risks, uncertainties, and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. Risks and uncertainties that may cause our actual results to differ include risks inherent in our business, reimbursement and access to our products, the impact of competition and other important factors discussed in the “Risk Factors” section of our Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on February 25, 2026, as well as any subsequent filings with the SEC. Any forward-looking statements that the Company makes in this press release are made pursuant to the Private Securities Litigation Reform Act of 1995, as amended, and speak only as of the date of this press release. Except as required by law, we undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available.
Contacts:
Media
Amanda Sheldon, head of Corporate Communications
media@arcutis.com
Investors
Brian Schoelkopf, head of Investor Relations
ir@arcutis.com
